; incentives Section 506C(g) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(g) ) is amended— (1) in paragraph (1), by striking the Secretary may and inserting the Secretary shall, as appropriate ; (2) in paragraph (1), by inserting prioritize and before expedite the review ; and (3) in paragraph (2), by inserting prioritize and before expedite an inspection . 4122. Additional manufacturer reporting requirements in response to drug shortages (a) Expansion To include active pharmaceutical ingredients Subsection (a) of section 506C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c ) is amended— (1) in paragraph (1)(C), by inserting or any such drug that is critical to the public health during a public health emergency determined under section 319 of the Public Health Service Act after during surgery ; and (2) in the flush text at the end— (A) by inserting , or a discontinuance or an interruption in the manufacture of the active pharmaceutical ingredients of such drug, before that is likely ; and (B) by adding at the end the following: Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, as applicable; if an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated medical devices used for preparation or administration included in the finished dosage form is a reason for, or a risk factor in, such discontinuation or interruption; the expected duration of the interruption